Compare SKIL & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKIL | ELOX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | 2247 | 7 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 41.0M |
| IPO Year | N/A | N/A |
| Metric | SKIL | ELOX |
|---|---|---|
| Price | $6.57 | $12.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 114.4K | 55.8K |
| Earning Date | 04-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $10.00 |
| 52 Week High | $18.45 | $15.00 |
| Indicator | SKIL | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 40.75 |
| Support Level | $6.30 | $10.51 |
| Resistance Level | $8.11 | $14.37 |
| Average True Range (ATR) | 0.53 | 1.67 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 30.59 | 23.02 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.